National Cancer Institute National Cancer Institute
U.S. National Institutes of Health National Cancer Institute
NCI Home Cancer Topics Clinical Trials Cancer Statistics Research & Funding News About NCI
714-X (PDQ®)
Patient VersionHealth Professional VersionLast Modified: 06/12/2009



Purpose of This PDQ Summary






Overview






General Information






History






Laboratory/Animal/Preclinical Studies






Human/Clinical Studies







Adverse Effects






Overall Level of Evidence for 714-X






Changes to This Summary (06/12/2009)






More Information



Page Options
Print This Page  Print This Page
Print This Document  Print Entire Document
View Entire Document  View Entire Document
E-Mail This Document  E-Mail This Document
Quick Links
Director's Corner

Dictionary of Cancer Terms

NCI Drug Dictionary

Funding Opportunities

NCI Publications

Advisory Boards and Groups

Science Serving People

Español
Quit Smoking Today
NCI Highlights
Office of Biorepositories and Biospecimen Research

The Nation's Investment in Cancer Research FY 2010

Report to Nation Finds Declines in Cancer Incidence, Death Rates
Adverse Effects

It is claimed that 714-X is nontoxic in the manufacturer-recommended dose range.[1] Reviewed in [2] The only described side effects of treatment with this compound are local redness, tenderness, and swelling at injection sites. Reviewed in [2]

References

  1. 714X Technical Data. Rock Forest, Canada: CERBE Distribution, Inc. Available online. Last accessed June 11, 2009. 

  2. Kaegi E: Unconventional therapies for cancer: 6. 714-X. Task Force on Alternative Therapeutic of the Canadian Breast Cancer Research Initiative. CMAJ 158 (12): 1621-4, 1998.  [PUBMED Abstract]

Back to TopBack to Top

< Previous Section  |  Next Section >


A Service of the National Cancer Institute
Department of Health and Human Services National Institutes of Health USA.gov